Trial reportTechniques in coloproctology2025
Indocyanine green (ICG) fluorescence guided lymph node mapping for determination of resection margins in colon cancer - ISCAPE trial.
Trial report in Techniques in coloproctology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fluorescence-guided surgery in colorectal cancer: current evidence, quantitative advances, and future perspectives.Annals of coloproctology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndocyanine green (ICG) lymphangiography for colon cancer has been regarded as a sentinel lymph node (LN) detection tool, but its repeatedly reported suboptimal sensitivity rates suggest that approach aiming to define locoregional lymphatic collector margins might be more efficient in guiding surgeon's decision making. Thus, present study was designed to determine if sensitivity of the latter approach is sufficient to guide resection margins' selection in colon cancer surgery.
methodsThis is a prospective, single-centre, single-arm phase II interventional trial, including patients with histologically confirmed colon adenocarcinoma. ICG was injected subserosally in the beginning of operation, fluorescence was assessed 30 min after injection or later, when it became detectable. Primary endpoint was proportion of pN + patients in whom all metastatic lymph nodes were located within the area of fluorescence of lymphatics (AFL). Secondary endpoints included feasibility, safety, lymphatic spread patterns and proportion of resections modified based on ICG mapping.
resultsBetween 26 July 2022 and 27 February 2024, 101 patients underwent colectomies with intraoperative ICG lymphatic mapping. AFL was registered in all cases. Average lateral spread was 5.87 ± 3.20 proximally and 5.89 ± 2.54 cm distally. In two of 46 pN + cases affected LNs were discovered beyond AFL. ICG lymphatic mapping sensitivity was found to be 95.6%, which was beyond 0.960-0.990 interval, so null hypothesis was retained.
conclusionsIn this trial, metastatic LNs were confined within ICG AFL in 95.6% of pN + cases. Although the predefined sensitivity threshold was not met, the result suggests potential for ICG mapping to guide resection margins in colon cancer surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.